RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aurinia Pharmaceuticals Stock

Aurinia Pharmaceuticals Market capitalization 2024

Aurinia Pharmaceuticals Market capitalization

729.7 M USD

Ticker

AUPH

ISIN

CA05156V1022

WKN

A1W7D4

In 2024, Aurinia Pharmaceuticals's market cap stood at 729.7 M USD, a -7.43% increase from the 788.29 M USD market cap in the previous year.

The Aurinia Pharmaceuticals Market capitalization history

YEARMarket Capitalization (undefined USD)
20230.98
20221.06
20211.58
20201.35
20190.48
20180.34
20170.33
20160.07
20150.08
20140.08
20130
20120
20110
20100
20090
20080
20070
20060
20050
20040

Aurinia Pharmaceuticals Aktienanalyse

What does Aurinia Pharmaceuticals do?

Aurinia Pharmaceuticals Inc is a biopharmaceutical company that was founded in Canada in 1993. The company specializes in developing therapy options for autoimmune diseases, particularly the treatment of Lupus Nephritis, a condition where the immune system mistakenly attacks the body's own cells and damages the kidneys. Aurinia specializes in the field of biologic medications, which are based on proteins that naturally occur in the human body. These medications are used to modulate the immune system and "suppress" specific cells that trigger autoimmune diseases. Aurinia's main product is Voclosporin, an orally administered drug specifically developed for the treatment of Lupus Nephritis. Clinical trials have shown promising results, and Voclosporin received approval from the US FDA in 2020. Voclosporin is now successfully used in several countries worldwide. Aurinia also conducts research and development in other areas of autoimmune diseases. Another potential application is the treatment of Vogt-Koyanagi-Harada disease, a rare eye condition also attributed to autoimmune diseases. Aurinia's business model is based on developing new therapies that address the medical needs of patients with autoimmune diseases. The company focuses on close collaboration with medical professionals, patients and their families, as well as regulatory authorities. Aurinia has also formed partnerships with other companies and non-profit organizations to support its research and development and enhance access to its products in different countries. Aurinia's success relies on the extensive experience and expertise of its employees in biotechnological research, development and manufacturing of biologic medications, as well as its close partnerships with world-leading physicians in the field of autoimmune diseases. The company is committed to constantly improving the quality of its products and services to enhance patients' quality of life and effectively treat their disease. Overall, Aurinia Pharmaceuticals is a company dedicated to developing innovative therapies for autoimmune diseases, particularly for the treatment of Lupus Nephritis. The company strives to meet the medical needs of patients, their families, and medical professionals while also improving the entire ecosystem of medical care in this field. Aurinia's goal is to provide patients with better and more effective therapies and treatments to improve their health and well-being. Aurinia Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Aurinia Pharmaceuticals's Market Capitalization

Aurinia Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Aurinia Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Aurinia Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Aurinia Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Aurinia Pharmaceuticals stock

What is the current Aurinia Pharmaceuticals market capitalization?

The current market capitalization of Aurinia Pharmaceuticals is 729.7 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Aurinia Pharmaceuticals.

How has the market capitalization of Aurinia Pharmaceuticals developed in recent years?

The market capitalization of Aurinia Pharmaceuticals has increased/decreased by -7.43% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Aurinia Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Aurinia Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Aurinia Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Aurinia Pharmaceuticals pay?

Over the past 12 months, Aurinia Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aurinia Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aurinia Pharmaceuticals?

The current dividend yield of Aurinia Pharmaceuticals is .

When does Aurinia Pharmaceuticals pay dividends?

Aurinia Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aurinia Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aurinia Pharmaceuticals located?

Aurinia Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aurinia Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aurinia Pharmaceuticals from 10/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2024.

When did Aurinia Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/20/2024.

What was the dividend of Aurinia Pharmaceuticals in the year 2023?

In the year 2023, Aurinia Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aurinia Pharmaceuticals pay out the dividend?

The dividends of Aurinia Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aurinia Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aurinia Pharmaceuticals

Our stock analysis for Aurinia Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aurinia Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.